Compare CCL & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCL | RMD |
|---|---|---|
| Founded | 1972 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 36.4B |
| IPO Year | 1987 | 1995 |
| Metric | CCL | RMD |
|---|---|---|
| Price | $28.03 | $253.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 12 |
| Target Price | $35.90 | ★ $291.10 |
| AVG Volume (30 Days) | ★ 20.8M | 880.0K |
| Earning Date | 12-19-2025 | 01-29-2026 |
| Dividend Yield | ★ 2.08% | 0.93% |
| EPS Growth | ★ 40.51 | 29.59 |
| EPS | 2.02 | ★ 9.77 |
| Revenue | ★ $26,622,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | $5.63 | $9.85 |
| Revenue Next Year | $3.68 | $7.34 |
| P/E Ratio | ★ $14.32 | $26.36 |
| Revenue Growth | 6.40 | ★ 9.36 |
| 52 Week Low | $15.07 | $199.92 |
| 52 Week High | $32.89 | $293.81 |
| Indicator | CCL | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 53.46 |
| Support Level | $31.35 | $240.00 |
| Resistance Level | $32.47 | $261.36 |
| Average True Range (ATR) | 0.89 | 5.40 |
| MACD | -0.51 | 1.27 |
| Stochastic Oscillator | 5.06 | 60.56 |
Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.